Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)—a systematic review protocol

BACKGROUND: Multiple sclerosis (MS) is an inflammatory and degenerative disease of the central nervous system with an increasing worldwide prevalence. Since 1993, more than 15 disease-modifying immunotherapies (DMTs) have been licenced and have shown moderate efficacy in clinical trials. Based on th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lehnert, Thomas, Röver, Christian, Köpke, Sascha, Rio, Jordi, Chard, Declan, Fittipaldo, Andrea V., Friede, Tim, Heesen, Christoph, Rahn, Anne C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250266/
https://www.ncbi.nlm.nih.gov/pubmed/35778721
http://dx.doi.org/10.1186/s13643-022-01997-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250266/
https://www.ncbi.nlm.nih.gov/pubmed/35778721
http://dx.doi.org/10.1186/s13643-022-01997-2

Ejemplares similares